Description
What is Cartalax?
Cartalax (Ala-Glu-Asp) is a synthetic tripeptide bioregulator developed through cytomedine research — a field pioneered by Russian scientists, most notably Professor Vladimir Khavinson, focused on short-chain peptides derived from specific tissue types. The logic behind cytomedines is straightforward: each tissue produces its own signalling peptides, and by identifying and replicating those sequences, researchers can explore whether they influence the behaviour of cells within that tissue.
Cartalax was developed to target cartilage specifically. Its three-amino-acid sequence closely mirrors sequences found in type XI collagen — a structural protein native to cartilage — which is thought to be the basis of its tissue-selective activity. Research into Cartalax has focused primarily on chondrocyte function, cartilage matrix integrity, and the molecular pathways involved in joint tissue degeneration.
What Researchers Are Exploring
Cartilage Matrix Support
In vitro studies on human articular chondrocytes have found that Cartalax exposure increased the activity of genes responsible for producing type II collagen and aggrecan — the two main building blocks of cartilage. Both are essential for healthy cartilage structure and its ability to handle load, and their decline is a hallmark of joint degeneration. The ability of a short peptide to influence their expression at the gene level is what makes Cartalax a point of interest in tissue-specific research.
Chondrocyte Signalling & Cellular Survival
Cartilage has an unusually limited ability to repair itself. It has no direct blood supply, low cell density, and chondrocytes — the cells responsible for maintaining cartilage — become progressively less responsive to repair signals with age. Research has explored Cartalax’s potential to support chondrocyte survival and shift cellular behaviour from a degenerative state toward matrix maintenance, including studies looking at reduced cell death signalling under inflammatory conditions.
Anti-Inflammatory Research
Pro-inflammatory signals and enzymes are primary drivers of cartilage breakdown in degenerative joint conditions. Studies have explored Cartalax’s ability to reduce the activity of these enzymes and modulate inflammatory signalling pathways within cartilage tissue — potentially helping to slow the processes that outpace repair in ageing and injured joints.
Longevity & Age-Related Joint Decline
As part of broader cytomedine research on tissue-specific ageing, Cartalax has been investigated for its potential role in preserving cartilage integrity over time. The premise is that as the body’s own signalling peptides decline with age, supplementing with tissue-targeted bioregulators may help maintain the cellular communication needed for tissue upkeep. This sits within the wider longevity peptide research space, alongside compounds like Epitalon and Pinealon.
Post-Injury Cartilage Research
Following joint injury, inflammatory cascades and altered mechanical loading can accelerate cartilage degradation. Researchers have explored Cartalax in the context of post-traumatic joint stress, looking at whether supporting chondrocyte signalling may help limit secondary degeneration.
Worth Noting
Cartalax is notable for its tissue specificity — its short sequence appears to direct activity toward cartilage rather than acting broadly across multiple tissue types. This specificity is the core principle of cytomedine research, and it distinguishes Cartalax from general repair peptides like BPC-157 or TB-500. Most of the existing research originates from Russian clinical and preclinical work, with in vitro studies demonstrating measurable changes in gene expression.
For research use only.Not approved by the TGA or FDA.
